Research Signal – Source date 2022-04-17
For some people with advanced liver cancer, surgery may become possible after drug treatment. That sequence is called conversion therapy: treatment is given first, with surgery considered afterward if the situation allows. A 2022 review describes preliminary clinical experience with this approach, including a combination of an immune checkpoint inhibitor and an antiangiogenic drug.
The review says that in China a high proportion of patients with hepatocellular carcinoma, a form of liver cancer, present with advanced disease. For some of them, reaching surgery after drug treatment might open another route through care. The review does not suggest that this route is available to everyone.
Treatment first, surgery considered later
Conversion therapy aims to make surgery possible after initial treatment. The combination named in this review’s title consists of two types of drug: an immune checkpoint inhibitor and an antiangiogenic drug. The review surveys clinical experience with conversion treatments followed by surgery for advanced liver cancer.
The drug combination is only one part of the question. The key uncertainty is whether treatment can make surgery possible for a particular patient, and under what conditions.
A possibility in preliminary clinical experience
The review’s authors say that successful conversion therapy followed by surgery is achievable for a population of patients with advanced disease. They describe the research as preliminary and acknowledge controversy. This supports a measured conclusion: reaching surgery after treatment has been reported as a possibility for some patients, but the review’s abstract does not tell us how often it happens for people receiving the named combination.
It also gives no basis here for estimating a survival advantage or making a quantified safety claim. Nor does it provide a rule for deciding who is likely to reach surgery. A review of earlier clinical experience can bring reports together, but it is not itself a new trial or a recommendation for every person with advanced liver cancer.
Where this research could lead
A dependable way to identify who might reach surgery could make this treatment sequence more predictable for patients and clinicians. For a patient whose initial plan does not include surgery, clearer criteria could make it easier to assess whether that option becomes possible after treatment. That future would build on the review’s reported experience of treatment followed by surgery, while requiring stronger evidence about selection and outcomes than the review provides.
One useful milestone would be a prospective study that states who enters the study, sets surgery criteria in advance, reports how many participants actually undergo surgery, and follows their outcomes. Those details could show whether the possibility described in the review can be assessed consistently for a defined group.
Key Sources
- Primary source: Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
DOI or Journal Page · Review or Meta-Analysis · 2022-04-17
Keep exploring